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Background: Obesity is associated with an increased risk of esophageal adenocarcinoma (EAC) and a decreased
risk of esophageal squamous cell carcinoma (ESCC). However, little is known about the risk of EAC and ESCC related
to other metabolic risk factors. We aimed to examine the risk of EAC and ESCC in relation to metabolic risk factors,
separately and combined in a prospective cohort study.
Methods: The Metabolic Syndrome and Cancer cohort includes prospective cohorts in Austria, Norway and
Sweden, with blood pressure, lipids, glucose and BMI available from 578 700 individuals. Relative risk (RR) for EAC
and ESCC was calculated using Cox’s proportional hazards analysis for metabolic risk factors categorized into
quintiles and transformed into z-scores. The standardized sum of all z-scores was used as a composite score for the
metabolic syndrome (MetS).
Results: In total, 324 histologically verified cases of esophageal cancer were identified (114 EAC, 184 ESCC and 26
with other histology). BMI was associated with an increased risk of EAC (RR 7.34 (95% confidence interval, 2.88-18.7)
top versus bottom quintile) and negatively associated with the risk of ESCC (RR 0.38 (0.23-0.62)). The mean value of
systolic and diastolic blood pressure (mid blood pressure) was associated with the risk of ESCC (RR 1.77 (1.37-2.29)).
The composite MetS score was associated with the risk of EAC (RR 1.56 (1.19-2.05) per one unit increase of z-score)
but not ESCC.
Conclusions: In accordance with previous studies, high BMI was associated with an increased risk of EAC and a
decreased risk of ESCC. An association between high blood pressure and risk of ESCC was observed but alcohol
consumption is a potential confounding factor that we were not able to adjust for in the analysis. The MetS was
associated with EAC but not ESCC. However this association was largely driven by the strong association between
BMI and EAC. We hypothesize that this association is more likely to be explained by factors directly related to
obesity than the metabolic state of the MetS, considering that no other metabolic factor than BMI was associated
with EAC.
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Esophageal cancer is the eighth most common cancer and
the sixth most common cause of cancer-related mortality
worldwide [1]. Esophageal cancers can be divided into
esophageal squamous cell carcinoma (ESCC) and esopha-
geal adenocarcinoma (EAC). These two cancer types have
distinct epidemiological characteristics [2]. The incidence of
EAC has risen dramatically in Western countries during
the last decades, particularly among white males [3,4], while
the incidence of ESCC has been stable or slightly decreasing
[2]. Obesity, gastro-esophageal reflux disease and tobacco
smoking have been demonstrated to be risk factors for
EAC while Helicobacter pylori seropositivity seems to have
a protective effect [5]. Established risk factors for ESCC are
tobacco smoking, alcohol consumption, low intake of fruits
and vegetables and low socioeconomic status [5].
The metabolic syndrome (MetS) is a cluster of meta-
bolic risk factors, including obesity, hypertension, insulin
resistance/hyperglycemia and dyslipidemia that has been
shown to be associated with cardiovascular disease [6,7].
There is now accumulating evidence that the MetS also
may be an important risk factor for several specific can-
cers as well as overall cancer mortality [8]. A recent
meta-analysis has reported an increased risk for liver,
colorectal, bladder, pancreatic, breast and endometrial
cancer related to the MetS [8].
There is strong epidemiological evidence for an associ-
ation between obesity and an increased risk of EAC [9] and
a decreased risk of ESCC [10]. However, knowledge on the
risk of esophageal cancer in relation to other MetS compo-
nents is limited. Previous epidemiological studies have
not demonstrated any clear evidence for an association be-
tween hyperglycemia and esophageal cancer overall, but a
significant association in subanalysis of esophageal cancer
with mortal outcome and esophageal cancer among men
[11-13]. An association between blood lipids and esopha-
geal cancer has been reported from one study that was not
able to adjust for BMI or smoking habits [14]. It is note-
worthy that all these studies share the methodological prob-
lem of using all esophageal cancer as endpoint. Considering
the highly separate biological and epidemiological profile of
EAC and ESCC [2], the lack of differentiation between
EAC and ESCC significantly limits the scientific value of all
these studies. Studies on the association between hyperten-
sion and EAC and ESCC are lacking.
The aim of the present study was to investigate the asso-
ciation between BMI, blood pressure, glucose, cholesterol,
and triglycerides, both separately and combined, and the
risk of EAC and ESCC in a large prospective cohort.
Methods
The metabolic syndrome and cancer project (Me-Can)
The Metabolic syndrome and Cancer project (Me-Can)
was initiated in 2006 with the specific aim to investigatethe association between components of the metabolic
syndrome and overall- and site-specific cancer risk
[15-22]. The Me-Can cohort consists of seven prospect-
ive cohorts in Austria, Norway and Sweden and has
been described in detail previously [23]. In brief, after
exclusion of subjects with unrealistic or missing baseline
data or prevalent cancer diagnosis, the Me-Can cohort
consists of data on 578 700 subjects (289 866 men and
288 834 women). Ethical clearance was obtained from
each national ethical committee in Austria, Norway and
Sweden.
Assessment of exposure at baseline investigation
Study participants were subjected to health examination
(s) between 1972 and 2005. The data collection proced-
ure and details on measurement methods have been de-
scribed in a previous publication [23]. In brief weight
and height were measured without shoes with light in-
door clothes in all cohorts. Blood pressure was measured
in the supine or sitting position. Smoking habits were
assessed by use of a self-administered questionnaire in
all cohorts with the exception for the Austrian cohort
(Vorarlberg Health Monitoring and Prevention Program),
where the examining physician asked subjects about their
smoking habits. Study subjects were not requested to fast
before baseline examination in all cohorts, but fasting time
before blood sampling was recorded in all subjects. Blood,
plasma or serum levels of glucose, total cholesterol and
triglycerides were analyzed.
End-point assessment
The seven cohorts were linked to the respective National
registers for cancer diagnosis, migration status (if avail-
able) and vital status. End of follow-up was 2006 in the
Swedish cohorts, 2005 in the Norwegian cohorts and
2003 in the Austrian cohorts. Migration status was avail-
able in all cohorts except for the Australian cohort [23].
Subjects with an incident diagnosis of esophageal cancer
were identified using the International Classification
of Diseases (ICD), seventh edition (ICD-7), code 150.
Morphology coding was available according to several dif-
ferent classification systems (C24 [24], Manual of Tumor
Nomenclature (MOTNAC), ICD-Oncology (ICD-O) 1,
ICD-O-2 and SNOMED) depending on study cohort and
time of diagnosis. Only cases that were histologically veri-
fied were considered for the study.
Statistical analysis
Quintile cut-off values were calculated separately in
groups defined by cohort and sex for BMI and mid BP
((systolic BP + diastolic BP)/2) and in groups defined by
cohort, sex and categories of fasting time (<4 hours,
4–8 hours and >8 hours) for glucose, cholesterol and
triglycerides. In order to reduce the risk of a reverse
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examination. Subjects were followed until the date of
diagnosis of esophageal cancer, death, migration, or end
of follow-up, whichever occurred first. Incident cancers
at other sites were not considered a criterion for censor-
ing. Cox proportional hazards analysis was used to cal-
culate relative risks (RR) with 95% confidence interval
(CI) for EAC and ESCC related to quintile levels of all
five components of the MetS. The proportional hazards
assumption was met in all analyses as verified by log-log
plots. Attained age was used as the underlying time
scale. All models were stratified by cohort and by cat-
egories of birth-year (before 1923, 1923–1930, 1931–
1938, 1939–1946, 1947–1954, 1955 and later). Relative
risks were adjusted for age at baseline as a continuous
variable and for sex, smoking status and quintile levels
of BMI as categorical variables. We decided to include
BMI in the final model due to the association between
BMI and EAC and ESCC and the well-established asso-
ciation between BMI and other metabolic factors. The
p-value for trend over quintiles refers to the Wald test
of a linear risk estimate.
In order to make the variables comparable on a con-
tinuous scale and to create a combined MetS variable,
the z-score standardization was used ((exposure level –
mean)/standard deviation (SD)), resulting in a z-score of
the exposures with a mean of 0 and a SD of 1. Glucose and
triglycerides were log-transformed before standardization,
as they were skewed and had outliers. BMI and mid blood
pressure were standardized separately in groups defined by
cohort and sex. Log (glucose), cholesterol and log (triglyc-
erides) were standardized in groups based on cohort,
sex and fasting time. The MetS score was calculated
by summarizing the five individual z-scores before
standardization. Cox proportional hazards regression was
used to calculate RRs for EAC and ESCC related to the
continuous z-score of the exposures. Again, attained age
was used as time scale and the model was stratified by co-
hort and birth-year categories. In the analysis of the MetS,
all estimates were subsequently adjusted for sex, age at
baseline and smoking status. Relative risks related to the
composite MetS score were adjusted for sex, age at base-
line and smoking status. Additionally, the adjusted model
of individual metabolic factors (BMI, mid blood pressure,
glucose, cholesterol and triglycerides) included all meta-
bolic factors at the same time.
RRs for EAC and ESCC were also assessed for all sep-
arate exposures as continuous variables (per five unit in-
crement for BMI, per one unit increment of glucose,
cholesterol and triglycerides and per 10 unit increment
for mid BP). In this analysis, subjects with glucose levels
> 10 mmol/l and triglycerides > 6 mmol/l were classified
as outliers and excluded. RRs were adjusted for age
at baseline, smoking status and all metabolic factors.Interactions between smoking and additional factors
were tested by including cross-product terms in the re-
gression models. A p-value of < 0.05 was considered to
be indicative of a statistically significant interaction.
In addition to quintile categorization, BMI and blood
pressure variables were further categorized according to
World Health Organization (WHO) criteria for obesity
[25] and European Society of Hypertension (ESH) and
European Society of Cardiology (ESC) criteria for hyper-
tension [26]. Underweight was defined as BMI ≤ 18.4,
normal weight as BMI = 18.5-25.0, over weight as BMI =
25.0-29.9 and obesity as BMI ≥ 30 [25]. Blood pressure
was classified as normal if systolic BP was < 140 and dia-
stolic BP was < 90. Definition of severity of hypertension
was grade I = systolic BP 140–159 or diastolic BP 90–99,
grade II systolic BP = 160–179 or diastolic BP = 100–109
and grade III systolic BP ≥ 180 or diastolic BP ≥ 110. RR
for EAC and ESCC related to WHO categories of BMI
and ESH categories of hypertension were calculated
using Cox’s proportional hazards regression stratifying
and adjusting for the same variables as above.
Correction of a random error
In the analysis of exposure categorized in quintiles, re-
gression dilution ratios (RDR) were calculated based on
repeated health examinations in 133,820 subjects in the
full Me-Can database in order to adjust RRs for random
errors in the measurement of exposure variables at base-
line [27,28], this process has been described in detail
previously [13]. In brief, only measurements in the same
cohort with the same fasting time before any incident
cancer diagnosis were used. Correction of the RRs for
RDRs was obtained by dividing the estimated parameter
with RDR [exp (log (RR)/RDR)]. The estimated RDR
were as follows; BMI 0.902, mid BP 0.544, glucose 0.278,
cholesterol 0.657, triglycerides 0.505 and MetS 0.688.
When more than one variable with a random error was
included in the analysis such as when z-score variables
were analyzed, the RDR correction was not considered ap-
propriate. In those situations a regression calibration
model (RC) was used instead [27,29]. With this method,
the exposure measured with error (the observed measure-
ment) was replaced with a predicted value calculated from
a regression model, again with age at baseline, birth year,
fasting time, smoking status and time from baseline as
fixed effects and cohort as random effect. The corrected
measurement was then used in risk model estimation.
All statistical analyses were performed in SPSS Statistics
19.0 (Chicago, Illinois) except calculation of RDR and re-
gression calibration that was calculated in R, version 2.7.2.
Results
Baseline characteristics for the Me-Can cohort and cases
of EAC and ESCC are presented in Table 1. Fifty percent
Table 1 Baseline characteristics
Cases Total cohort1
Adenocarcinoma Squamous cell
carcinoma
Other or undifferentiated
morphology
All cases
Subjects, n 114 184 26 324 577259
Sex Male 102 (89.5) 144 (78.3) 22 (84.6) 268 (82.7) 288930 (50.1)
Female 12 (10.5) 40 (21.7) 4 (15.4) 56 (17.3) 288329 (49.9)
Age at baseline, mean (SD) 49.6 (10.1) 51.0 (10.9) 51.2 (10.1) 50.5 (10.5) 44.0 (11.7)
Cohort, n (%) Oslo 13 (11.4) 37 ((20.1) 5 (19.2) 55 (17.0) 16714 (2.9)
NCS 31 (27.2) 29 (15.8) 4 (15.4) 64 (19.8) 50922 (8.8)
CONOR 10 (8.8) 14 (7.6) 3 (11.5) 27 (8.3) 109403 (19.0)
40-y 5 (4.4) 6 (3.3) 1 (3.8) 12 (3.7) 128742 (22.3)
VHM&PP 16 (14.0) 40 (21.7) 5 (19.2) 61 (18.8) 159444 (27.6)
VIP 16 (14.0) 8 (4.3) 1 (3.8) 25 (7.7) 79360 (13.7)
MPP 23 (20.2) 50 (27.2) 7 (26.9) 80 (24.7) 32674 (5.7)
Fasting time, n (%) < 4 hrs 43 (37.7) 64 (34.8) 8 (30.8) 115 (35.5) 242246 (42.0)
4-8 hrs 14 (12.3) 14 (7.6) 5 (19.2) 33 (10.2) 57409 (9.9)
> 8 hrs 57 (50.0) 106 (57.6) 13 (50.0) 176 (54.3) 277604 (48.1)
BMI, mean (SD) 27.1 (3.8) 24.0 (3.3) 26.0 (4.2) 25.3 (3.8) 25.3 (4.0)
Mid BP2 mmHg, mean (SD) 110.6 (12.9) 112.4 (15.3) 111.9 (12.7) 111.7 (14.3) 104.4 (13.7)
Glucose mmol/l, median (IQR) 5.4 (4.8-5.4) 5.3 (4.7-5.3) 5.1 (4.6-5.6) 5.3 (4.7-5.9) 5.1 (4.6-5.6)
Cholesterol mmol/l, mean (SD) 6.1 (1.1) 6.2 (1.1) 6.4 (1.3) 6.2 (1.1) 5.7 (1.2)
Triglycerides mmol/l, median (IQR) 1.63 (1.11-2.43) 1.44 (1.02-2.11) 1.82 (1.12-2.80) 1.57 (1.05-2.33) 1.29 (0.91-1.91)
Smoking status, n (%) Never 25 (21.9) 29 (15.8) 4 (15.4) 58 (17.9) 257721 (44.6)
Former 36 (31.6) 25 (13.6) 5 (19.2) 66 (20.4) 158358 (27.4)
Current 52 (45.6) 129 (70.1) 17 (65.4) 198 (61.1) 159624 (27.7)
Missing 1 (0.9) 1 (0.5) 0 2 (0.6) 1556 (0.3)
1After exclusion of 1441 subjects with a follow-up less than 1 year.
2Mid blood pressure = [(systolic blood pressure + diastolic blood pressure)/2] mm Hg).
Abbreviations: Oslo The Oslo study I cohort, NCS The Norwegian County Study, CONOR The cohort of Norway, 40-y: The Age 40-programme, VHM&PP The Vorarl-
berg Health Monitoring and Prevention Program, VIP The Västerbotten Intervention Project, MPP The Malmö Preventive Project, BMI body mass index (kg/m2).
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mean age at baseline was 44.0 years, mean BMI was
25.3, 27.7% were current smokers, 27.4% were former
smokers and 44.6% were never-smokers. Mean time of
follow-up was 12 years.
Body mass index and risk of esophsageal
adenocarcinoma
There was a statistically significant association between
BMI and the risk of EAC with a clear dose–response re-
lationship over quintiles (adjusted RR for top versus bot-
tom quintile of BMI was 7.34 (95% CI 2.88-18.68) and
corresponding RDR corrected adjusted RR was 9.18
(95% CI, 3.24-25.96)) (Table 2). This association was also
statistically significant when BMI was standardized into
z-scores (RR 1.64 (95% CI, 1.30-2.07) per one unit in-
crease of calibrated z-score) (Table 3). The RRs of EAC
related to WHO categories of BMI were 3.29 (95% CI,
1.82-5.95) for BMI ≥30 and 2.32 (95% CI, 1.51-3.57)for BMI 25.0-29.9, adjusted for sex, age and smoking
status using subjects with BMI of 18.5-24.9 as refer-
ence category (Table 4). There was no interaction
between smoking status and investigated metabolic
factors as risk factors for EAC with the exception for
an interaction between triglycerides and former (ver-
sus never) smokers (p = 0.01) (Table 5). BMI was sig-
nificantly associated with the risk of EAC among
current and former smokers and there was a non-
significant tendency towards an association among
never smokers (Table 5).Other metabolic risk factors and the risk of esophsageal
adenocarcinoma
Mid BP, glucose, cholesterol and triglycerides were not
associated with the risk of EAC (Table 2 and 3). There
was a statistically significant association between the
composite MetS score and the risk of EAC (RR 1.56
Table 2 Relative risks for esophageal cancer related to different metabolic risk factors in quintiles
Exposure Adenocarcinoma Squamous cell carcinoma
Quintile Mean (SD) Cases (n) Age and cohort
stratified RR
Adjusted
RR1
Adjusted, RDR
corrected RR1
Cases
(n)
Age and cohort
stratified RR
Adjusted RR1 Adjusted, RDR
corrected RR1
BMI 1 20.7 (1.5) 5 1.00 1.00 1.00 55 1.00 1.00 1.00
2 23.0 (1.1) 18 3.13 (1.16–8.44) 3.37 (1.25–9.10) 3.86 (1.28–11.66) 29 0.44 (0.28–0.70) 0.50 (0.32–0.79) 0.47 (0.28–0.77)
3 24.7 (1.0) 18 2.81 (1.04–7.60) 3.17 (1.17–8.57) 3.61 (1.19–10.91) 46 0.62 (0.42–0.92) 0.76 (0.51–1.12) 0.73 (0.47–1.14)
4 26.8 (1.0) 31 4.41 (1.71–11.39) 5.19 (2.00–13.42) 6.24 (2.17–17.97) 30 0.37 (0.23–0.57) 0.46 (0.30–0.72) 0.42 (0.26–0.70)
5 31.3 (3.3) 42 5.96 (2.34–15.16) 7.34 (2.88–18.68) 9.18 (3.24–25.96) 24 0.29 (0.18–0.47) 0.38 (0.23–0.62) 0.34 (0.20–0.58)
Ptrend <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Adjusted RR per increment of 51 1.64 (1.35–2.00) 1.78 (1.45–2.17) 0.56 (0.44–0.70) 0.62 (0.50–0.79)
Mid blood pressure, mmHg 1 88 (5.7) 14 1.00 1.00 1.00 21 1.00 1.00 1.00
2 97 (4.1) 18 1.12 (0.56–2.25) 0.99 (0.49–2.00) 0.99 (0.27–3.58) 30 1.29 (0.74–2.26) 1.47 (0.84–2.58) 2.04 (0.73–5.70)
3 103 (3.8) 22 1.24 (0.63–2.44) 1.15 (0.58–2.27) 1.29 (0.37–4.50) 23 0.87 (0.48–1.58) 1.14 (0.63–2.08) 1.28 (0.43–3.83)
4 110 (4.1) 25 1.13 (0.58–2.19) 1.01 (0.52–1.98) 1.02 (0.30–3.50) 49 1.55 (0.93–2.61) 2.27 (1.35–3.83) 4.51 (1.72–11.81)
5 125 (10.4) 35 1.32 (0.70–2.51) 1.09 (0.57–2.10) 1.17 (0.35–3.90) 60 1.59 (0.95–2.66) 2.60 (1.54–4.39) 5.79 (2.21–15.20)
Ptrend 0.44 0.81 0.035 <0.0001
Adjusted RR per increment
of 10 mmHg1
1.09 (0.95–1.25) 1.03 (0.89–1.19) 1.17 (1.05–1.29) 1.30 (1.17–1.44)
Glucose, mmol/L 1 4.1 (0.5) 19 1.00 1.00 1.00 34 1.00 1.00 1.00
2 4.7 (0.3) 21 1.06 (0.57–1.97) 1.07 (0.57–2.01) 1.29 (0.14–12.21) 33 0.96 (0.59–1.55) 1.04 (0.64–1.69) 1.16 (0.20–6.55)
3 5.1 (0.3) 20 0.96 (0.51–1.81) 0.95 (0.51–1.80) 0.85 (0.09–8.32) 38 1.07 (0.69–1.70) 1.20 (0.75–1.91) 1.90 (0.35–10.27)
4 5.5 (0.3) 28 1.28 (0.71–2.31) 1.32 (0.73–2.38) 2.69 (0.32–22.70) 31 0.88 (0.54–1.44) 1.02 (0.62–1.68) 1.08 (0.18–6.43)
5 6.8 (1.9) 26 1.07 (0.59–1.95) 1.04 (0.57.1.90) 1.14 (0.13–10.12) 48 1.21 (0.77–1.89) 1.44 (0.92–2.27) 3.76 (0.74–19.17)
Ptrend 0.62 0.70 0.50 0.14
Adjusted RR per increment
of 1 mmol/l2,3
1.14 (0.93–1.38) 1.12 (0.92–1.38) 1.16 (0.99–1.35) 1.22 (1.04–1.42)
Cholesterol, mmol/L 1 4.2 (0.5) 13 1.00 1.00 1.00 22 1.00 1.00 1.00
2 5.0 (0.3) 25 1.60 (0.82–3.15) 1.48 (0.75–2.91) 1.82 (0.65–5.08) 30 1.09 (0.63–1.89) 1.08 (0.62–1.88) 1.13 (0.49–2.62)
3 5.6 (0.3) 18 1.01 (0.49–2.08) 0.93 (0.45–1.92) 0.90 (0.30–2.69) 36 1.16 (0.68–1.99) 1.20 (0.70–2.05) 1.32 (0.59–2.99)
4 6.2 (0.3) 27 1.34 (0.68–2.63) 1.22 (0.62–2.40) 1.36 (0.49–3.80) 44 1.26 (0.75–2.12) 1.32 (0.78–2.21) 1.52 (0.69–3.35)
5 7.4 (0.8) 31 1.34 (0.69–2.62) 1.22 (0.63–2.37) 1.35 (0.49–3.72) 51 1.32 (0.79–2.21) 1.42 (0.85–2.37) 1.70 (0.78–3.71)
Ptrend 0.68 0.86 0.22 0.12
Adjusted RR per increment
of 1 mmol/l2
0.99 (0.84–1.17) 0.94 (0.80–1.10) 1.06 (0.94–1.21) 1.08 (0.95–1.22)
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Table 2 Relative risks for esophageal cancer related to different metabolic risk factors in quintiles (Continued)
Triglycerides, mmol/L 1 0.72 (0.17) 14 1.00 1.00 1.00 27 1.00 1.00 1.00
2 1.03 (0.21) 18 1.20 (0.60–2.42) 1.03 (0.51–2.07) 1.05 (0.26–4.22) 39 1.28 (0.78–2.09) 1.26 (0.77–2.06) 1.57 (0.59–4.17)
3 1.33 (0.29) 16 0.98 (0.48–2.02) 0.78 (0.38–1.60) 0.61 (0.15.2.55) 34 1.05 (0.63–1.74) 1.05 (0.63–1.75) 1.11 (0.40–3.04)
4 1.77 (0.42) 33 1.95 (1.04–3.65) 1.42 (0.75–2.69) 2.00 (0.56–7.09) 39 1.14 (0.70–1.87) 1.22 (0.74–2.01) 1.48 (0.55–3.99)
5 3.12 (1.54) 28 1.60 (0.84–3.06) 1.05 (0.54–2.05) 1.11 (0.30–4.15) 44 1.24 (0.77–2.02) 1.45 (0.87–2.39) 2.07 (0.77–5.61)
Ptrend 0.038 0.51 0.58 0.22
Adjusted RR per increment
of 1 mmol/l2,4
1.35 (1.12–1.61) 1.13 (0.93–1.38) 1.15 (0.98–1.34) 1.19 (1.01–1.40)
All analyses were stratified by study cohort and birth-year category. See text for correction of regression dilution bias.
1Adjusted for sex, age at baseline (continuous) smoking status and quintiles of BMI. 2Adjusted for age at baseline (continuous), smoking status, quintiles of BMI and fasting time. 3Outliers >10 mmol/l are excluded.
4Outliers >6 mmol/l are excluded.
Abbreviations: CI confidence interval, RR relative risk, SD standard deviation, BMI body mass index, Mid BP: mid blood pressure, RDR regression dilution ratio.
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Table 3 Risk for esophageal cancer for continuous z-scores of single metabolic factors and the metabolic syndrome
Exposure Adenocarcinoma (n = 114) Squamous cell carcinoma (n = 184)
RR model 11 RR model 22 Regression calibrated RR3 RR model 11 RR model 22 Regression calibrated RR3
BMI 1.57 (1.35–1.83) 1.58 (1.34–1.87) 1.64 (1.30–2.07) 0.69 (0.58–0.81) 0.60 (0.50–0.72) 0.50 (0.40–0.63)
Mid blood pressure 1.10 (0.92–1.32) 0.99 (0.81–1.21) 0.95 (0.66–1.39) 1.28 (1.13–1.46) 1.40 (1.23–1.60) 1.77 (1.37–2.29)
Glucose 1.04 (0.86–1.24) 0.97 (0.80–1.17) 0.99 (0.49–1.99) 1.11 (0.98–1.27) 1.11 (0.97–1.27) 1.40 (0.85–2.31)
Cholesterol 1.02 (0.84–1.23) 0.95 (0.77–1.17) 0.92 (0.66–1.29) 1.07 (0.92–1.24) 1.08 (0.92–1.26) 1.10 (0.85–1.41)
Triglycerides 1.20 (0.99–1.45) 1.05 (0.85–1.30) 1.13 (0.71–1.80) 0.99 (0.86–1.16) 1.05 (0.88–1.24) 1.03 (0.71–1.49)
MetS4 1.36 (1.13–1.64) – 1.56 (1.19–2.05) 1.06 (0.91–1.24) – 1.09 (0.87–1.36)
Relative risk with 95% confidence interval for esophageal adenocarcinoma and squamous cell carcinoma for continuous z-score of single metabolic factors and
the combined z-score for the metabolic syndrome.
1Relative risk from Cox regression models, with attained age as time scale, stratified by cohort and categories of birth year. Adjusted for sex, age at baseline
and smoking.
2As model 1 but in addition adjusted for the z-score of analyzed factors i.e. BMI, mid BP, glucose, cholesterol and triglycerides.
3As model 2 and corrected by regression calibration, see text.
4Z score for MetS is adjusted for sex, age at baseline and smoking status. Corrected for regression dilution bias, see text.
Abbreviations: MetS metabolic syndrome, BMI body mass index, RR relative risk.
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ite MetS score) (Table 3).
Body mass index and risk of esophageal squamous cell
carcinoma
Higher BMI was statistically significantly associated with
a decreased risk of ESCC (adjusted RR for top versus
bottom quintile of BMI was 0.38 (95% CI, 0,23-0,62) and
corresponding RDR corrected adjusted RR was 0.34
(95% CI, 0.20-0.58) (Table 2). When BMI classified into
WHO categories was analyzed, a negative dose–response
relationship was observed. The adjusted RR was 0.67
(95% CI, 0.49-0.93) for BMI 25–29.9, and 0.47 (95% CI,Table 4 Risk for esophageal cancer in relation to clinical cate
Exposure Category Aden
Crude RR
BMI in WHO categories ≤ 18.4 -
18.5–25.0 Reference
25.0–29.9 2.53 (1.66–3.88)
≥ 30 2.69 (1.50–4.85)
≥ 25 2.57 (1.70–3.88)
ESH/ESC hypertension criteria3 Normal Reference
Grade 1 1.13 (0.74–1.72)
Grade 2 1.47 (0.84–2.57)
Grade 3 0.93 (0.33–2.62)
Grade 1–3 1.19 (0.81–1.74)
Ptrend 0.39
Relative risks with 95% confidence interval for incident esophageal adenocarcinom
in clinical criteria for obesity and hypertension. All analyses were stratified by study
1Adjusted for sex, age at baseline (continuous) and smoking status.
2Adjusted for sex, age at baseline (continuous), smoking status and BMI (continuou
3European Society of Hypertension (ESH) and European Society of Cardiology (ESC)
diastolic BP < 90. Grade I hypertension: systolic BP 140–159 or diastolic BP 90–99, g
BP ≥ 180 or diastolic BP ≥ 110.
Abbreviations: RR relative risk, CI confidence interval, BMI body mass index, WHO Wo
Society of Cardiology.0.24-0.94) for BMI ≥30, using BMI 18.5-24.9 as reference
category (Table 4). This association was statistically sig-
nificant also when BMI was analyzed as a continuous
variable (RR 0.62 (95% CI 0.50-0.79) per increment of
5 in BMI) (Table 2), and standardized into z-scores
(RR 0.50 (95% CI, 0.40-0.63) per one unit increase in
z-score) (Table 3). There was no interaction between
smoking status and any of the investigated metabolic
factors as risk factors for ESCC. The association between
high BMI and decreased risk of ESCC was statistically
significant in current smokers. In never and former
smokers there was a similar trend that, however, did not
reach statistical significance (Table 5).gories of obesity and hypertension
ocarcinoma Squamous cell carcinoma
Adjusted RR1 Crude RR Adjusted RR2
- 1.68 (0.62–4.56) 1.54 (0.56–4.19)
Reference Reference Reference
2.32 (1.51–3.57) 0.65 (0.47–0.90) 0.67 (0.49–0.93)
3.29 (1.82–5.95) 0.39 (0.19–0.77) 0.47 (0.24–0.94)
2.47 (1.63–3.74) 0.60 (0.44–0.82) 0.64 (0.47–0.87)
Reference Reference Reference
0.90 (0.59–1.32) 1.34 (0.96–1.87) 1.61 (1.15–2.26)
1.11 (0.63–1.96) 1.42 (0.89–2.26) 1.98 (1.23–3.17)
0.66 (0.23–1.87) 1.96 (1.10–3.59) 2.95 (1.62–5.37)
0.93 (0.63–1.37) 1.41 (1.04–1.91) 1.77 (1.30–2.42)
0.72 0.01 <0.0001
a and squamous cell carcinoma related to BMI and blood pressure categorized
cohort and birth-year category.
s).
criteria for hypertension: Normal blood pressure (BP): systolic BP < 140 and
rade II: systolic BP = 160–179 or diastolic BP = 100–109 and grade III: systolic
rld Health Organization, ESH European Society of Hypertension, ESC European
Table 5 Risk for esophageal cancer in relation to metabolic risk factors stratified for smoking
Smoking
status
Exposure Adenocarcinoma Squamous cell carcinoma
RR model 11 RR model 22 Regression
calibrated RR3
Interaction4 p-value RR model 11 RR model 22 Regression
calibrated RR3
Interaction4 p-value
Never smoker BMI 1.22 (0.83–1.77) 1.30 (0.87–1.94) 1.28 (0.75–2.19) 0.72 (0.47–1.09) 0.67 (0.43–1.06) 0.61 (0.35–1.07)
Mid BP 1.08 (0.73–1.60) 1.11 (0.73–1.67) 1.15 (0.52–2.53) 1.23 (0.89–1.70) 1.35 (0.97–1.89) 1.75 (0.93–3.30)
Glucose 1.19 (0.86–1.65) 1.22 (0.86–1.71) 2.00 (0.55–7.36) 1.03 (0.75–1.43) 1.01 (0.71–1.43) 0.91 (0.25–3.32)
Cholesterol 0.81 (0.53–1.26) 0.82 (0.50–1.34) 0.82 (0.38–1.18) 0.93 (0.63–1.37) 0.90 (0.59–1.37) 0.84 (0.43–1.65)
Triglycerides 0.77 (0.49–1.20) 0.71 (0.44–1.17) 0.45 (0.16–1.27) 0.97 (0.66–1.44) 1.07 (0.69–1.65) 1.10 (0.43–2.83)
Mets 1.07 (0.69–1.65) - 1.10 (0.58–2.08) 0.98 (0.66–1.47) - 0.98 (0.54–1.75)
Former smoker BMI 1.87 (1.49–2.35) 1.89 (1.44–2.47) 2.14 (1.44–3.18) 0.07 0.91 (0.59–1.40) 0.78 (0.49–1.24) 0.62 (0.35–1.10) 0.59
Mid BP 1.14 (0.83–1.56) 0.96 (0.68–1.36) 0.91 (0.47–1.77) 0.28 1.52 (1.09–2.11) 1.53 (1.09–2.16) 1.93 (0.99–3.75) 0.47
Glucose 0.86 (0.61–1.23) 0.73 (0.51–1.06) 0.43 (0.11–1.64) 0.46 1.30 (0.98–1.72) 1.27 (0.94–1.71) 2.80 (0.99–7.93) 0.14
Cholesterol 1.15 (0.83–1.58) 1.04 (0.72–1.50) 1.01 (0.56–1.80) 0.14 1.14 (0.77–1.69) 1.12 (0.73–1.70) 1.21 (0.61–2.41) 0.56
Triglycerides 1.54 (1.11–2.13) 1.28 (0.88–1.85) 1.96 (0.87–4.39) 0.01 1.02 (0.68–1.52) 0.92 (0.59–1.45) 0.73 (0.28–1.94) 0.68
MetS 1.60 (1.16–2.21) - 1.99 (1.25–3.16) 0.08 1.39 (0.94–2.04) - 1.61 (0.92–2.82) 0.21
Current smoker BMI 1.54 (1.22–1.94) 1.52 (1.18–1.95) 1.53 (1.09–2.16) 0.35 0.63 (0.52–0.77) 0.55 (0.45–0.68) 0.46 (0.35–0.61) 0.41
Mid BP 1.13 (0.87–1.48) 1.02 (0.76–1.37) 1.03 (0.59–1.80) 0.71 1.26 (1.07–1.48) 1.39 (1.18–1.63) 1.75 (1.28–2.38) 0.76
Glucose 1.03 (0.77–1.36) 0.95 (0.71–1.29) 0.96 (0.32–2.88) 0.97 1.08 (0.92–1.27) 1.09 (0.92–1.29) 1.26 (0.67–2.37) 0.83
Cholesterol 1.03 (0.78–1.35) 0.93 (0.69–1.27) 0.89 (0.54–1.47) 0.36 1.09 (0.92–1.29) 1.11 (0.92–1.33) 1.14 (0.84–1.53) 0.44
Triglycerides 1.22 (0.93–1.61) 1.09 (0.80–1.49) 1.24 (0.63–2.43) 0.07 1.00 (0.83–1.19) 1.07 (0.87–1.31) 1.09 (0.70–1.69) 0.90
MetS 1.37 (1.04–1.81) - 1.58 (1.05–2.37) 0.38 1.01 (0.84–1.22) - 1.02 (0.78–1.34) 0.96
Relative risk for esophageal cancer in relation to continuous z-score of metabolic factors and the composite metabolic syndrome score, stratified for smoking status.
1Relative risk from Cox regression models with attained age as time scale, stratified by cohort and categories of birth year within the model, adjusted for sex and age at baseline.
2As model 1 but in addition adjusted for all metabolic factors.
3Adjusted as model 2. Corrected by regression calibration, see text.
4Each metabolic factor multiplied by smoking status (current or former) was entered in the analysis as an interaction term. Adjusted as model.
Abbreviations: RR relative risk, MetS metabolic syndrome, BMI body mass index, Mid BP mid blood pressure.
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http://www.biomedcentral.com/1471-2407/14/103Blood pressure and the risk of esophageal squamous cell
carcinoma
Higher mid BP was associated with an increased risk of
ESCC. The adjusted RR for ESCC was 2.60 (95% CI
1.54-4.39) for top versus bottom quintile of mid BP and
corresponding RDR corrected adjusted RR was 5.79
(95% CI, 2.21-15.20) (Table 2). In the analysis of mid
BP as a continuous variable the RR for ESCC was 1.30
(95% CI, 1.17-1.44) (Table 2) per increment of 10 mmHg
and RR for mid BP standardized into z-score was 1.77
(95% CI, 1.37-2.29) per one unit of z-score increment
(Table 3). Using ESH/ESC criteria for hypertension
revealed a clear dose–response relationship between
hypertension grade and risk of ESCC with a RR of 1.61
(95% CI, 1.15-2.26), 1.98 (95% CI 1.23-3.17) and 2.95
(95% CI, 1.62-5.37) for grade I, II and III hypertension
respectively (p-value for trend <0.001) (Table 4). There
was no statistically significant interaction between smok-
ing and mid BP (Table 5). Estimates of RR for ESCC
related to mid BP z-scores were similar in all strata of
smoking status, albeit statistically significant only in
current smokers (Table 5).
Other metabolic risk factors and the risk of esophageal
squamous cell carcinoma
There was no association between glucose, cholesterol
or triglycerides and risk of ESCC (Table 2 and 3), with
the exception for a borderline significant association be-
tween triglycerides as a continuous variable in the fully
adjusted model (RR 1.19 (95% CI, 1.01-1.40) per incre-
ment of 1 mmol/l). The composite variable for the MetS
was not statistically significantly associated with risk of
ESCC (RR 0.92 (95% CI, 0.79-1.08) per 1 unit increment
of the composite MetS score) (Table 3).
Discussion
The association between metabolic factors and the risk
of the two dominating types of esophageal cancer, EAC
and ESCC, was investigated in this large prospective co-
hort study. There was a strong association between high
BMI and an increased risk of EAC and a decreased risk
of ESCC. Mid BP was associated with an increased risk
of ESCC. The composite MetS score was associated with
an increased risk of EAC but not with the risk of ESCC.
The association between overweight and EAC is
known from several previous studies [9,30-33]. In a meta
analysis from 2006, Kubo et al. reported a pooled OR of
1.7 (95% CI, 1.6-1.9) for EAC related to overweight and
obesity compared to normal weight [9]. Smith et al. re-
ported a pooled RR of 1.54 (95% CI, 1.39-1.71) per
increment of 5 in BMI for all identified case–control
studies and Engeland et al. reported a RR of 1.53
(95% CI, 1.30-1.79) in a Norwegian cohort that is
partly overlapping the Norwegian Me-Can cohort. Theassociation between BMI and the risk of EAC in the
present study is slightly stronger than those reported
in previous meta analyses with a RR of 1.78 (95%
CI 1.45-2.17) per increment of 5 in BMI and a RR of
2.47 (95% CI, 1.63-3.74) for overweight and obesity
compared to normal weight. Misclassification of EAC as
ESCC can be expected to attenuate risk estimates given
the known inverse association between BMI and ESCC.
It is possible that this kind of bias has been less import-
ant in the present study, considering the high quality of
the national cancer registries that were used.
Two different causal links between obesity and EAC can
be hypothesized. One possible mechanism is through and
increased risk for gastroesophageal reflux. Obesity is asso-
ciated with an increased risk of gastro-esophageal reflux
[34] which in turn is associated with the development of
intestinal metaplasia in the distal esophagus, i.,e Barrett’s
esophagus [35], a pre malignant condition associated with
the risk of EAC [36].
Another possible mechanism for the association be-
tween obesity and EAC is through a hormonal and/or
metabolic systemic disequilibrium related to the MetS
[37]. The MetS has been demonstrated to be associated
with several site-specific cancers, including liver, colorec-
tal, breast, pancreatic, urinary bladder, and endometrial
cancer [8]. The mechanisms for the association between
the MetS and cancer are not fully characterized. Chronic
low-grade inflammation, high levels of trophic hormones
(ie insulin and insulin-like growth factor) or lifestyle-
related factors related to the MetS have been proposed
as putative mechanisms [8].
In the present study, we found a statistically significant
association between the surrogate score for the MetS
and the risk of EAC. However, BMI was the only meta-
bolic factor with a statistically significant association with
the risk of EAC. Therefore, we consider that our findings
suggest that obesity leading to gastro-esophageal reflux
and esophageal dysplasia may be the more important
mechanism. Nevertheless, this does not exclude a role
for metabolic state related to the MetS for the develop-
ment of EAC. High leptin levels and low levels of high
molecular weight adipnectin have been associated with
an increased risk for progression from Barrett’s esopha-
gus to EAC after adjustment for relevant other risk fac-
tors, including BMI [38].
The inverse association between BMI and the risk for
ESCC demonstrated in the present study has been ob-
served in several previous studies [10,39,40]. In a meta-
analysis by Smith et al., data from 3 cohort studies were
pooled and the RR for ESCC per increment of 5 in BMI
was estimated to 0.69 (95% CI, 0.63-0.75) [10]. The in-
verse association between BMI and risk of ESCC in the
present study was similar to the above-mentioned stud-
ies with a RR of 0.62 (95% CI, 0.50-0.79) per increment
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and ESCC, Steffen et al. recently observed a positive as-
sociation between waist-hip-ratio and risk of ESCC in a
model adjusted for BMI [33]. We had no possibility to
investigate the association between waist-hip ratio and
ESCC risk since this information was not available in
the Me-Can cohort. The association between BMI
and ESCC was only statistically significant in current
smokers and data on smoking dose was not available for
the adjusted analysis. As a consequence, even though
the analysis was adjusted for smoking status, smoking
dose may have been a confounder in the association be-
tween BMI and the risk of ESCC found in this study,
considering that smoking is associated with low BMI
and a well-established risk factor for ESCC [41].
We found a strong and dose dependent association be-
tween mid BP and risk of ESCC. However, alcohol con-
sumption is a known risk factor for hypertension [42]
and has also consistently been associated with the risk
for ESCC [5]. It is therefore possible that alcohol con-
sumption is a confounder in the observed association
between hypertension and ESCC. An increased risk of
esophageal cancer in general related to hypertension di-
agnosed below the age of 60 years was recently reported
in a study from the Saskatchewan Health database [43],
but we know of no studies to date, exploring the possible
association between hypertension and ESCC or EAC.
The association between hypertension and cancer in
general has been explored in previous studies finding ei-
ther no [44] or a modest positive association [45,46].
An association between high blood glucose and an in-
creased risk of cancer overall has been reported in several
prospective studies [11,13]. Proposed mechanisms for this
association include a direct mitotic effect of insulin-like
growth factor and oxidative stress related to hypergly-
cemia [47]. We did not find any association between
serum glucose and EAC and no significant association be-
tween glucose and ESCC except for when glucose was en-
tered as a continuous variable. Previous studies on the
association between esophageal cancer and serum glucose
have been conflicting, demonstrating no association for
overall esophageal cancer in most studies [11-13] but posi-
tive associations in subgroups of hyperglycemic subjects
(i.e. men with diabetes [12,48], fatal esophageal cancer
[13] or fatal esophageal cancer among men [11]). A limita-
tion to all these studies is that there was no differentiation
between EAC and ESCC. The association between dia-
betes and esophageal cancer has recently been investigated
in a metaanalysis where an increased risk was found
among men but not women [49]. Subanalysis of three
studies separating EAC from ESCC revealed that diabetes
was associated with EAC [49].
Well-designed studies on the association between
blood lipids and different subtypes of esophageal cancerare lacking. A positive association between esophageal
cancer and both triglycerides and low-density lipopro-
tein cholesterol/high-density lipoprotein cholesterol has
been reported in a recent cohort study [14]. However,
BMI and smoking was not adjusted for in that study.
We observed a statistically significant trend over triglycer-
ide quintiles and risk of EAC in crude analysis that disap-
peared when BMI was adjusted for, indicating that BMI
may have been a confounder in the above-mentioned
study [14]. We did not find any association between tri-
glycerides or cholesterol and the risk of ESCC. To the best
of our knowledge, there is no evidence for such an associ-
ation in the literature.
Major strengths of the present study are the prospect-
ive design and the large size of the cohort. The large
proportion of subjects with repeated measurements
in the cohort enabled us to adjust for random error
in measurement of metabolic factors. National cancer
registries in Sweden, Norway and Austria have a
previously been demonstrated to be highly accurate
[19,50,51] assuring a high quality in the end-point as-
sessment. The possibility to differentiate between EAC
and ESCC was another important strength. As demon-
strated in the present study, these two types of esopha-
geal cancer have very different risk factor profile and the
value of previous studies analyzing all esophageal cancer
together can be questioned. Differentiation between dis-
tal EAC and adenocarcinoma of the gastric cardia may
in some cases be difficult and some misclassification of
gastric cardia cancers as EAC has most probably oc-
curred in this study. However, adenocarcinoma of the
gastric cardia and EAC are associated with BMI and
smoking in a similar manner [39] and limited misclassi-
fication between these cancers will not have any major
impact on investigated risk factors. Differences in meas-
urement methods between the different cohorts is a
limitation to the study that we have tried to overcome
by using cohort specific cut-offs for quintiles and z-score
standardization. Another shortcoming of the study is the
lack of information on ethnicity, considering the previ-
ously demonstrated association between EAC and white
race [3]. The above-mentioned use of cohort specific cut-
offs and z-score standardization and the relative homo-
geneity of the individual cohorts have probably reduced
the impact of this bias. Information on smoking habits
was limited. Subjects could be classified as never, current
or former smokers but quantitative data was lacking. In
order to compensate for this, positive findings were reana-
lyzed in separate strata of smoking habits. The associa-
tions between BMI and EAC, BMI and ESCC and Mid BP
and ESCC were homogenous, even though not statistically
significant, in all strata of smoking habits including never
smokers. The possibility of a type I error should also be
kept in mind since multiple comparisons were made.
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This study confirms the previously described association
between a high BMI and an increased risk of EAC. A
significant association was found between the surrogate
score for the MetS and the risk of EAC. However, con-
sidering that no other metabolic risk factors were associ-
ated with EAC risk, we hypothesize that it is not the
hormonal metabolic state related to the MetS that is
the probable cause of the association between BMI
and EAC. More likely, other factors associated with
obesity such as increased risk of gastro esophageal reflux
disease may play a role. We were also able to confirm
the previously described negative association between
BMI and ESCC and we found a positive association be-
tween blood pressure and ESCC that, to the best of our
knowledge, has never been described before. However,
this finding has to be confirmed in studies where proper
adjustment for alcohol consumption is possible.
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